Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionXBI - SPDR(R) S&P(R) Biotech ETF
Latest Disclosed Ownership2,268,292 shares
Latest Disclosed Value $ 56,162,909
XBI - SPDR(R) S&P(R) Biotech ETF reports 11.70% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - XBI - SPDR(R) S&P(R) Biotech ETF filed a NPORT-P form disclosing ownership of 2,268,292 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $56,162,910 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 2,568,932 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -11.70% during the quarter. The current value of the position is $71,428,515 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,268,292 -300,640 -11.70 56,163 -6.33 0.7554
2026-02-26 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,568,932 540,362 26.64 59,959 50.04 0.7639
2025-11-26 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,028,570 858,052 73.31 39,963 57.33 0.6997
2025-08-28 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,170,518 -112,150 -8.74 25,400 -18.34 0.5258
2025-05-28 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,282,668 -51,094 -3.83 31,105 11.74 0.6080
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 1,333,762 -74,147 -5.27 27,836 -0.55 0.4370
2024-11-25 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,407,909 -511,609 -26.65 27,989 -5.87 0.3637
2024-08-28 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,919,518 -2,136,048 -52.67 29,733 -54.01 0.4173
2024-05-28 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 4,055,566 913,227 29.06 64,646 22.38 0.8561
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,142,339 -955,052 -23.31 52,823 10.28 0.7557
2023-11-28 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,097,391 -2,072,301 -33.59 47,898 -42.24 0.8714
2023-08-28 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 6,169,692 1,861,181 43.20 82,921 16.08 1.2745
2023-05-30 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 4,308,511 -446,819 -9.40 71,435 -19.24 1.1031
2023-02-28 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 4,755,330 318,091 7.17 88,449 55.37 1.0933
2022-11-28 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,437,239 932,974 26.62 56,930 131.76 0.8269
2022-08-26 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,504,265 921,328 35.67 24,565 14.72 0.3564
2022-05-27 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,582,937 200,118 8.40 21,413 32.74 0.3082
2022-02-25 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,382,819 -1,008,107 -29.73 16,132 -10.24 0.2270
2021-11-26 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,390,926 3,935 0.12 17,972 -7.72 0.2489
2021-08-23 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,386,991 -3,099,970 -47.79 19,475 -34.87 0.2645
2021-05-28 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,486,961 2,339,159 56.40 29,905 115.87 0.4112
2021-02-26 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 4,147,802 -1,576,152 -27.54 13,854 -18.51 0.1968
2020-11-27 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 5,723,954 1,167,380 25.62 17,000 -19.24 0.3243
2020-08-27 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 4,556,574 -1,030,566 -18.45 21,051 -2.13 0.4030
2020-06-01 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,587,140 236,138 4.41 21,510 7.20 0.6054
2020-02-27 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 5,351,002 3,686,427 221.46 20,066 127.04 0.4636
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,664,575 1,664,575 8,839 0.2407
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.